References
676. Collins RW, Anderson JW.
Medication cost savings associated with weight loss for obese
non-insulin-dependent diabetic men and women. Prev Med.
1995;24:369-374.
677. Darne B,
Nivarong M, Tugaye A, et al. Hypocaloric diet and antihypertensive drug
treatment. A randomized controlled clinical trial. Blood Press.
1993;2:130-135.
678. Gillett
PA, Eisenman PA. The effect of intensity controlled aerobic dance exercise on
aerobic capacity of middle-aged, overweight women. Res Nurs Health.
1987;10:383-390.
679. The
treatment of mild hypertension study. A randomized, placebo-controlled trial of
a nutritional-hygienic regimen along with various drug monotherapies. Arch
Intern Med. 1991;151:1413-1423.
680. Jeffery
RW, Gillum R, Gerber WM, Jacobs D, Elmer PJ, Prineas RJ. Weight and sodium
reduction for the prevention of hypertension: a comparison of group treatment
and individual counseling. Am J Public Health. 1983;73:691-693.
681. Kanaley
JA, Andresen-Reid ML, Oenning L, Kottke BA, Jensen MD. Differential health
benefits of weight loss in upper-body and lower-body obese women. Am J Clin
Nutr. 1993;57:20-26.
682.
Kumanyika SK. The impact of obesity on hypertension management in African
Americans. J Health Care Poor Underserved. 1997;8:352-364.
683. Mellies
MJ, Vitale C, Jandacek RJ, Lamkin GE, Glueck CJ. The substitution of sucrose
polyester for dietary fat in obese, hypercholesterolemic outpatients. Am J Clin
Nutr. 1985;41:1-12.
684. Page RC,
Harnden KE, Cook JT, Turner RC. Can lifestyles of subjects with impaired
glucose tolerance be changed? A feasibility study. Diabet Med.
1992;9:562-566.
685. Ready
AE, Drinkwater DT, Ducas J, Fitzpatrick DW, Brereton DG, Oades SC. Walking
program reduces elevated cholesterol in women postmenopause. Can J Cardiol.
1995;11:905-912.
686. Rigaud
D, Ryttig KR, Angel LA, Apfelbaum M. Overweight treated with energy restriction
and a dietary fibre supplement: a 6-month randomized, double-blind,
placebo-controlled trial. Int J Obes. 1990;14:763-769.
687. Rissanen
A, Pietinen P, Siljamaki-Ojansuu U, Piirainen H, Reissel P. Treatment of
hypertension in obese patients: efficacy and feasibility of weight and salt
reduction programs. Acta Med Scand. 1985;218:149-156.
688. Ryttig
KR, Rossner S. Weight maintenance after a very low calorie diet (VLCD) weight
reduction period and the effects of VLCD supplementation. A prospective,
randomized, comparative, controlled long-term trial. J Intern Med.
1995;238:299-306.
689. Singh
RB, Niaz MA, Bishnoi I, Singh U,Begum R, Rastogi SS. Effect of low energy diet
and weight loss on major risk factors, central obesity and associated
disturbances in patients with essential hypertension. J Hum Hypertens.
1995;9:355-362.
690. Singh
RB, Niaz MA, Ghosh S. Effect on central obesity and associated
disturbances of low-energy, fruit- and vegetable-enriched prudent diet in north
Indians. Postgrad Med J. 1994;70:895-900.
691. Singh RB, Rastogi SS, Sircar AR,
Mehta PJ, Sharma KK. Dietary strategies for risk-factor modification to prevent
cardiovascular diseases. Nutrition. 1991;7:210-214.
692. Stokholm
KH, Nielsen PE, Quaade F. Correlation between initial blood pressure and blood
pressure decrease after weight loss: a study in patients with jejunoileal
bypass versus medical treatment for morbid obesity. Int J Obes.
1982;6:307-312.
693. Walker
KZ, O'Dea K, Nicholson GC, Muir JG. Dietary composition, body weight, and
NIDDM. Comparison of high-fiber, high-carbohydrate, and modified-fat diets.
Diabetes Care. 1995;18:401-403.
694. Wing RR,
Jeffery RW, Burton LR, Thorson C, Kuller LH, Folsom AR. Change in waist-hip
ratio with weight loss and its association with change in cardiovascular risk
factors. Am J Clin Nutr. 1992;55:1086-1092.
695. Astrup
A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an
ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in
obese subjects on an energy-restricted diet. A double blind trial. Int J Obes
Relat Metab Disord. 1992;16:269-277.
696.
Connacher AA, Jung RT, Mitchell PE. Weight loss in obese subjects on a
restricted diet given BRL 26830A, a new atypical beta adrenoreceptor agonist.
BMJ (Clin Res Ed). 1988;296:1217-1220.
697. Daly PA,
Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin:
safety and efficacy for treatment of human obesity. Int J Obes Relat Metab
Disord. 1993;17 (Suppl 1):S73-S78.
698. Marin P,
Holmang S, Jonsson L, et al. The effects of testosterone treatment on body
composition and metabolism in middle-aged obese men. Int J Obes Relat Metab
Disord. 1992;16:991-997.
699.
Rasmussen MH, Andersen T, Breum L, Gotzsche PC, Hilsted J. Cimetidine
suspension as adjuvant to energy restricted diet in treating obesity. BMJ.
1993;306:1093-1096.
700. Coon PJ,
Bleecker ER, Drinkwater DT, Meyers DA, Goldberg AP. Effects of body composition
and exercise capacity on glucose tolerance, insulin, and lipoprotein lipids in
healthy older men: a cross-sectional and longitudinal intervention study.
Metabolism. 1989;38:1201-1209.
701. Franz
MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided
by dietitians in the management of non-insulin-dependent diabetes mellitus: a
randomized, controlled clinical trial. J Am Diet Assoc.
1995;95:1009-1017.
702. Milne
RM, Mann JI, Chisholm AW, Williams SM. Long-term comparison of three dietary
prescriptions in the treatment of NIDDM. Diabetes Care. 1994;17:74-80.
703. Ready
AE, Fitzpatrick DW, Boreskie SL, Hrycaiko DW. The response of obese females to
low impact exercise and diet counselling. J Sports Med Phys Fitness.
1991;31:587-595.
704. Singman
HS, Berman SN, Cowell C, Maslansky E, Archer M. The Anti-Coronary Club: 1957 to
1972. Am J Clin Nutr. 1980;33:1183-1191.
705. Suter E,
Marti B, Gutzwiller F. Jogging or walking comparison of health effects. Ann Epidemiol.
1994;4:375-381.
706. Viddal KO. Intestinal bypass. A
randomized, prospective clinical study of end-to-side and end-to-end
jejunoileal bypass. Scand J Gastroenterol. 1983;18:627-634.
707. Williams
PT, Wood PD, Haskell WL, Vranizan K. The effects of running mileage and
duration on plasma lipoprotein levels. JAMA. 1982;247:2674-2679.
708. Wing RR,
Marcus MD, Salata R, Epstein LH, Miaskiewicz S, Blair EH. Effects of a very
low-calorie diet on long-term glycemic control in obese Type 2 diabetic
subjects. Arch Intern Med. 1991;151:1334-1340.
709. Wing RR,
Blair E, Marcus M, Epstein LH, Harvey J. Year-long weight loss treatment for
obese patients with type II diabetes: does including an intermittent very
low-calorie diet improve outcome? Am J Med. 1994;97:354-362.
710. Drent
ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18-0647), a lipase
inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes
Relat Metab Disord. 1995;19:221-226.
711.
Pedrinola F, Sztejnsznajd C, Lima N, Halpern A, Medeiros-Neto G. The addition
of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized
clinical trial. Obes Res. 1996;4:549-554.
712. Connolly
VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients
with type 2 diabetes. Diabet Med. 1995;12:416-418.
713. Alpert
MA, Terry BE, Lambert CR, et al. Factors influencing left ventricular systolic
function in nonhypertensive morbidly obese patients, and effect of weight loss
induced by gastroplasty. Am J Cardiol. 1993;71:733-737.
714. Cairella
G, Cairella M, Marchini G. Effect of dietary fiber on weight correction after
modified fasting. Eur J Clin Nutr. 1995;49 (Suppl 3):S325-S327.
715. Foster
GD, Wadden TA, Peterson FJ, Letizia KA, Bartlett SJ, Conill AM. A controlled
comparison of three very low-calorie diets: effects on weight, body
composition, and symptoms. Am J Clin Nutr. 1992;55:811-817.
716. Hakala
P. Weight reduction programmes at a rehabilitation centre and a health centre
based on group counselling and individual support: short- and long-term
follow-up study. Int J Obes Relat Metab Disord. 1994;18:483-489.
717. Han TS,
Richmond P, Avenell A, Lean ME. Waist circumference reduction and
cardiovascular benefits during weight loss in women. Int J Obes Relat Metab
Disord. 1997;21:127-134.
718. Lean ME,
Han TS, Prvan T, Richmond PR, Avenell A. Weight loss with high and low
carbohydrate 1200 kcal diets in free living women. Eur J Clin Nutr.
1997;51:243-248.
719. Miura J,
Arai K, Tsukahara S, Ohno M, Ikeda Y. The long-term effectiveness of
combined therapy by behavior modification and very low-calorie diet: 2 years
follow up. Int J Obes. 1989;13 (Suppl 2):73-77.
720. Walker
KZ, O'Dea K, Johnson L, et al. Body fat distribution and non-insulin-dependent
diabetes: comparison of a fiber-rich, high-carbohydrate, low-fat (23%) diet and
a 35% fat diet high in monounsaturated fat. Am J Clin Nutr.
1996;63:254-260.
721. Foster GD, Wadden TA, Feurer ID,
et al. Controlled trial of the metabolic effects of a very low-calorie diet:
short- and long-term effects. Am J Clin Nutr. 1990;51:167-172.
722. Golay A,
Allaz AF, Morel Y, de Tonnac N, Tankova S, Reaven G. Similar weight loss with
low- or high-carbohydrate diets. Am J Clin Nutr. 1996; 63:174-178.
723. Rossner
S, Flaten H. VLCD versus LCD in long-term treatment of obesity. Int J Obes
Relat Metab Disord. 1997; 21:22-26.
724. Jarrett
RJ, Keen H, Murrells T. Changes in blood pressure and body weight over ten
years in men selected for glucose intolerance. J Epidemiol Community Health.
1987; 41:145-151.
725. Gwinup
G. Weight loss without dietary restriction: efficacy of different forms of
aerobic exercise. Am J Sports Med. 1987; 15:275-279.
726. Hespel
P, Lijnen P, Van Hoof R, et al. Effects of physical endurance training on the
plasma renin-angiotensin-aldosterone system in normal man. J Endocrinol.
1988;116:443-449.
727. King AC,
Taylor CB, Haskell WL, DeBusk RF. Influence of regular aerobic exercise on
psychological health: a randomized, controlled trial of healthy middle-aged
adults. Health Psychol. 1989;8:305-324.
728. Karvetti
RL, Knuts LR. Effects of comprehensive rehabilitation on weight reduction in
myocardial infarction patients. Scand J Rehabil Med. 1983;15:11-16.
729. Liao Y,
Emidy LA, Gosch FC, Stamler R, Stamler J. Cardiovascular responses to exercise
of participants in a trial on the primary prevention of hypertension. J
Hypertens. 1987;5:317-321.
730. Darga
LL, Carroll-Michals L, Botsford SJ, Lucas CP. Fluoxetine's effect on weight
loss in obese subjects. Am J Clin Nutr. 1991;54:321-325.
731. Elmer
PJ, Grimm R Jr, Laing B, et al. Lifestyle intervention: results of the
Treatment of Mild Hypertension Study (TOMHS). Prev Med. 1995;24:378-388.
732. Foreyt
JP, Ramirez AG, Cousins JH. Cuidando El Corazona weight-reduction intervention
for Mexican Americans. Am J Clin Nutr. 1991;53:1639S-1641S.
733. Hogan
RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled
trial of the gastric bubble for obesity. Gastrointest Endosc.
1989;35:381-385.
734. Marcus
MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. A double-blind,
placebo-controlled trial of fluoxetine plus behavior modification in the
treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry.
1990;147:876-881.
735. Stamler
J, Briefel RR, Milas C, Grandits GA, Caggiula AW. Relation of changes in
dietary lipids and weight, trial years 1-6, to changes in blood lipids in the
special intervention and usual care groups in the Multiple Risk Factor
Intervention Trial. Am J Clin Nutr. 1997;65:272S-288S.
736. Wing RR, Shoemaker M, Marcus MD,
McDermott M, Gooding W. Variables associated with weight loss and improvements
in glycemic control in type II diabetic patients in behavioral weight control
programs. Int J Obes. 1990;14:495-503.
737. DeLucia
JL, Kalodner CR, Horan JJ. The effect of two nutritional software programs used
as adjuncts to the behavioral treatment of obesity. J Subst Abuse.
1988-1989;1:203-208.
738. DeLucia
JL, Kalodner CR. An individualized cognitive intervention: does it increase the
efficacy of behavioral interventions for obesity? Addict Behav.
1990;15:473-479.
739.
Heitzmann CA, Kaplan RM, Wilson DK,
Sandler J. Sex differences in weight loss among
adults with type II diabetes mellitus. J Behav Med. 1987;10:197-211.
740. Jeffery
RW, Forster JL, French SA, et al. The Healthy Worker Project: a work-site
intervention for weight control and smoking cessation. Am J Public Health.
1993;83:395-401.
741. Jeffery
RW, Forster JL, Snell MK. Promoting weight control at the worksite: a pilot
program of self-motivation using payroll-based incentives. Prev Med.
1985;14:187-194.
742. Jones
SE, Owens HM, Bennett GA. Does behaviour therapy work for dietitians? An
experimental evaluation of the effects of three procedures in a weight
reduction clinic. Hum Nutr Appl Nutr. 1986;40:272-281.
743. Kalodner
CR, DeLucia JL. The individual and combined effects of cognitive therapy and
nutrition education as additions to a behavior modification program for weight
loss. Addict Behav. 1991;16:255-263.
744. Schwartz
SH, Inbar-Saban N. Value self-confrontation as a method to aid in weight loss.
J Pers Soc Psychol. 1988;54:396-404.
745. Breum L,
Astrup A, Andersen T, et al. The effect of long-term dexfenfluramine treatment
on 24-hour energy expenditure in man. A double-blind placebo controlled study.
Int J Obes. 1990;14:613-621.
746. Finer N,
Finer S, Naoumova RP. Drug therapy after very-low-calorie diets. Am J Clin
Nutr. 1992;56:195S-198S.
747. Pasquali
R, Cesari MP, Melchionda N, Stefanini C, Raitano A, Labo G. Does ephedrine
promote weight loss in low-energy-adapted obese women? Int J Obes.
1987;11:163-168.
748.
Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial
in weight control. Use of fenfluramine and phentermine alone and in
combination. Arch Intern Med. 1984;144:1143-1148.
749.
Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study.
II (weeks 34 to 104). An open-label study of continuous fenfluramine plus
phentermine versus targeted intermittent medication as adjuncts to behavior
modification, caloric restriction, and exercise. Clin Pharmacol Ther.
1992;51:595-601.
750. Bitsch
M, Skrumsager BK. Femoxetine in the treatment of obese patients in general
practice. A randomized group comparative study with placebo. Int J Obes.
1987;11:183-190.
751. Fernandez-Soto ML,
Gonzalez-Jimenez A, Barredo-Acedo F, Luna del Castillo JD, Escobar-Jimenez F.
Comparison of fluoxetine and placebo in the treatment of obesity. Ann Nutr
Metab. 1995;39:159-163.
752.
Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR.
Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes
Relat Metab Disord. 1994;18:129-135.
753. Cook RF,
Howard AN, Mills IH. Low-dose mianserin as adjuvant therapy in obese patients
treated by a very-low-calorie diet. Int J Obes. 1981;5:267-272.
754. Steel
JM, Munro JF, Duncan LJ. A comparative trial of different regimens of
fenfluramine and phentermine in obesity. Practitioner. 1973;211:232-236.
755. Sax L.
Yohimbine does not affect fat distribution in men. Int J Obes.
1991;15:561-565.
756. Benjamin
SB, Maher KA, Cattau EL Jr, et al. Double-blind controlled trial of the
Garren-Edwards gastric bubble: an adjunctive treatment for exogenous obesity.
Gastroenterology. 1988;95:581-588.
757.
Mathus-Vliegen EM, Tytgat GN, Veldhuyzen-Offermans EA. Intragastric balloon in
the treatment of super-morbid obesity. Double-blind, sham-controlled, crossover
evaluation of 500-milliliter balloon. Gastroenterology. 1990;99:362-369.
758. Bray GA,
Gray DS. Obesity. Part I Pathogenesis. West J Med. 1988;149:429-441.
759. Centers
for Disease Control and Prevention. Number and percentage of children and
adolescents who were overweight by gender and race/ethnicity: United States
NHANES III, 1988-1994. Morb Mortal Wkly Rep. 1997.
760. National
Center of Health Statistics. Centers for Disease Prevention and Control,
National Health and Nutrition Examination Survey, Phase III. Prevalence of
overweight in U.S. adults, by race/ethnicity, gender, and education,
1988-1991.
761. Centers
for Disease Control. Cardiac valvulopathy associated with exposure to
Fenfluramine or Dexfenfluramine: U.S. Department of Health and Human Services
interim public health recommendation, November 1997. MMWR Morb Mortal Wkly Rep.
1997;46:1061-1065.
762. American
Psychiatric Association. Task Force on DSM-IV, Diagnostic and Statistical
Manual of Mental Disorders : DSM-IV. 4th ed. Washington, DC: The Association;
1994.
763. Landin
K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an
impaired fibrinolytic activity and elevated plasminogen activator inhibitor-I.
Metabolism. 1990;39:1044-1048.
764. Reisin
E, Frohlich ED, Messerli FH, Dreslinski GR, et al. Cardiovascular changes after
weight reduction in obesity hypertension. Ann Intern Med. 1983;98:
315-319.
765. Tuck MI,
Sowers J, Dornfield L, et al. The effect of weight reduction on blood pressure
plasma renin activity and plasma aldosterone level in obese patients. N Engl J
Med. 1981;304:930-933.
766. Rocchini AP, Key J, Bondie D, et
al. The effect of weight loss on the sensitivity of blood pressure to sodium in
obese adolescents. N Engl J Med. 1989;321:580-585.
767.
Landsberg L, Krieger DR, Obesity, metabolism and the sympathetic nervous
system. Am J Hypertension. 1989;2:125S-132S.
768. Jacobs
DB, Sowers JR, et al. Effects of weight reduction on cellular cation metabolism
and vascular resistance. Hypertension. 1993;21:308-314.
769. Frohlich
ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med.
1992;327:998-1008.
|